Cargando…

Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury

Alcohol‐associated liver disease (ALD) is a spectrum of liver disorders ranging from steatosis to steatohepatitis, fibrosis, and cirrhosis. Alcohol‐associated hepatitis (AH) is an acute and often severe form of ALD with substantial morbidity and mortality. The mechanisms and mediators of ALD progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Warner, Dennis, Vatsalya, Vatsalya, Zirnheld, Kara H., Warner, Jeffrey B., Hardesty, Josiah E., Umhau, John C., McClain, Craig J., Maddipati, Krishnarao, Kirpich, Irina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183177/
https://www.ncbi.nlm.nih.gov/pubmed/34141982
http://dx.doi.org/10.1002/hep4.1686
_version_ 1783704331267080192
author Warner, Dennis
Vatsalya, Vatsalya
Zirnheld, Kara H.
Warner, Jeffrey B.
Hardesty, Josiah E.
Umhau, John C.
McClain, Craig J.
Maddipati, Krishnarao
Kirpich, Irina A.
author_facet Warner, Dennis
Vatsalya, Vatsalya
Zirnheld, Kara H.
Warner, Jeffrey B.
Hardesty, Josiah E.
Umhau, John C.
McClain, Craig J.
Maddipati, Krishnarao
Kirpich, Irina A.
author_sort Warner, Dennis
collection PubMed
description Alcohol‐associated liver disease (ALD) is a spectrum of liver disorders ranging from steatosis to steatohepatitis, fibrosis, and cirrhosis. Alcohol‐associated hepatitis (AH) is an acute and often severe form of ALD with substantial morbidity and mortality. The mechanisms and mediators of ALD progression and severity are not well understood, and effective therapeutic options are limited. Various bioactive lipid mediators have recently emerged as important factors in ALD pathogenesis. The current study aimed to examine alterations in linoleic acid (LA)‐derived lipid metabolites in the plasma of individuals who are heavy drinkers and to evaluate associations between these molecules and markers of liver injury and systemic inflammation. Analysis of plasma LA‐derived metabolites was performed on 66 individuals who were heavy drinkers and 29 socially drinking but otherwise healthy volunteers. Based on plasma alanine aminotransferase (ALT) levels, 15 patients had no liver injury (ALT ≤ 40 U/L), 33 patients had mild liver injury (ALT > 40 U/L), and 18 were diagnosed with moderate AH (mAH) (Model for End‐Stage Liver Disease score <20). Lipoxygenase‐derived LA metabolites (13‐hydroxy‐octadecadienoic acid [13‐HODE] and 13‐oxo‐octadecadienoic acid) were markedly elevated only in patients with mAH. The cytochrome P450‐derived LA epoxides 9,10‐epoxy‐octadecenoic acid (9,10‐EpOME) and 12,13‐EpOME were decreased in all patients regardless of the presence or absence of liver injury. LA‐derived diols 9,10‐dihydroxy‐octadecenoic acid (9,10‐DiHOME) and 12,13‐DiHOME as well as the corresponding diol/epoxide ratio were elevated in the mAH group, specifically compared to patients with mild liver injury. We found that 13‐HODE and 12,13‐EpOME (elevated and decreased, respectively) in combination with elevated interleukin‐1β as independent predictors can effectively predict altered liver function as defined by elevated bilirubin levels. Conclusion: Specific changes in LA metabolites in individuals who are heavy drinkers can distinguish individuals with mAH from those with mild ALD.
format Online
Article
Text
id pubmed-8183177
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81831772021-06-16 Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury Warner, Dennis Vatsalya, Vatsalya Zirnheld, Kara H. Warner, Jeffrey B. Hardesty, Josiah E. Umhau, John C. McClain, Craig J. Maddipati, Krishnarao Kirpich, Irina A. Hepatol Commun Original Articles Alcohol‐associated liver disease (ALD) is a spectrum of liver disorders ranging from steatosis to steatohepatitis, fibrosis, and cirrhosis. Alcohol‐associated hepatitis (AH) is an acute and often severe form of ALD with substantial morbidity and mortality. The mechanisms and mediators of ALD progression and severity are not well understood, and effective therapeutic options are limited. Various bioactive lipid mediators have recently emerged as important factors in ALD pathogenesis. The current study aimed to examine alterations in linoleic acid (LA)‐derived lipid metabolites in the plasma of individuals who are heavy drinkers and to evaluate associations between these molecules and markers of liver injury and systemic inflammation. Analysis of plasma LA‐derived metabolites was performed on 66 individuals who were heavy drinkers and 29 socially drinking but otherwise healthy volunteers. Based on plasma alanine aminotransferase (ALT) levels, 15 patients had no liver injury (ALT ≤ 40 U/L), 33 patients had mild liver injury (ALT > 40 U/L), and 18 were diagnosed with moderate AH (mAH) (Model for End‐Stage Liver Disease score <20). Lipoxygenase‐derived LA metabolites (13‐hydroxy‐octadecadienoic acid [13‐HODE] and 13‐oxo‐octadecadienoic acid) were markedly elevated only in patients with mAH. The cytochrome P450‐derived LA epoxides 9,10‐epoxy‐octadecenoic acid (9,10‐EpOME) and 12,13‐EpOME were decreased in all patients regardless of the presence or absence of liver injury. LA‐derived diols 9,10‐dihydroxy‐octadecenoic acid (9,10‐DiHOME) and 12,13‐DiHOME as well as the corresponding diol/epoxide ratio were elevated in the mAH group, specifically compared to patients with mild liver injury. We found that 13‐HODE and 12,13‐EpOME (elevated and decreased, respectively) in combination with elevated interleukin‐1β as independent predictors can effectively predict altered liver function as defined by elevated bilirubin levels. Conclusion: Specific changes in LA metabolites in individuals who are heavy drinkers can distinguish individuals with mAH from those with mild ALD. John Wiley and Sons Inc. 2021-02-09 /pmc/articles/PMC8183177/ /pubmed/34141982 http://dx.doi.org/10.1002/hep4.1686 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Warner, Dennis
Vatsalya, Vatsalya
Zirnheld, Kara H.
Warner, Jeffrey B.
Hardesty, Josiah E.
Umhau, John C.
McClain, Craig J.
Maddipati, Krishnarao
Kirpich, Irina A.
Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury
title Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury
title_full Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury
title_fullStr Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury
title_full_unstemmed Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury
title_short Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury
title_sort linoleic acid‐derived oxylipins differentiate early stage alcoholic hepatitis from mild alcohol‐associated liver injury
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183177/
https://www.ncbi.nlm.nih.gov/pubmed/34141982
http://dx.doi.org/10.1002/hep4.1686
work_keys_str_mv AT warnerdennis linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury
AT vatsalyavatsalya linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury
AT zirnheldkarah linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury
AT warnerjeffreyb linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury
AT hardestyjosiahe linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury
AT umhaujohnc linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury
AT mcclaincraigj linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury
AT maddipatikrishnarao linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury
AT kirpichirinaa linoleicacidderivedoxylipinsdifferentiateearlystagealcoholichepatitisfrommildalcoholassociatedliverinjury